PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

ASCO: Adding ribociclib to hormone therapy improves outcomes in patients with early breast cancer

The addition of ribociclib reduced the risk of the cancer returning by 25%

2023-06-02
(Press-News.org)  A study involving UCLA Jonsson Comprehensive Cancer Center researchers found when ribociclib, a targeted therapy drug, is added to hormone therapy there are a significant invasive disease-free survival benefit in patients with early hormone-receptor (HR) positive/HER2 negative breast cancer.

Researchers found that patients who took the combination therapy had substantially longer invasive disease-free survival compared to those who were treated with the hormone therapy alone, regardless of whether the cancer has spread to the lymph nodes. The addition of the targeted therapy reduced the risk of recurrence by 25%.

The results were shared today during the American Society of Clinical Oncology Annual Meeting by Dr. Dennis Slamon, chair of hematology-oncology and director of clinical and translational research at the UCLA Jonsson Comprehensive Cancer Center.

“The results from the clinical trial have immediate implications for patients,” said Slamon. “The findings show this combination is a treatment of choice for patients with stage 2 or stage 3 HR positive/HER2 negative breast cancer.”

HR positive/HER2 negative breast cancer is the most common subtype of the disease and accounts for nearly 70% of breast cancer cases in the Unites States.

Previously, Slamon and researchers at the Jonsson Cancer Center demonstrated that adding ribociclib, a cyclin-dependent kinase inhibitor, to the standard hormone therapy improves overall survival in both premenopausal and postmenopausal women with metastatic HR positive/HER2 negative breast cancer.

Slamon also led the discovery program that found that cyclin-dependent kinase inhibitors are effective in treating hormone receptor positive breast cancer. These drugs work by blocking the activity of cyclin-dependent kinase 4/6 enzymes, which promote cell division and cancer growth.

This work ultimately helped lead to the FDA approval of ribociclib and other related drugs to treat metastatic breast cancer. There are now three CDK4/6 inhibitors that have been approved by the FDA for combination treatment with standard hormone therapies in the metastatic setting.

Building on this past research, the team assessed whether the treatment combination could also improve outcomes in early breast cancer.

The clinical trial, called NATALEE, involved 5101 patients with stage 2 or stage 3 early HR positive/HER2 negative breast cancer. Patients were randomized into two arms: 2549 were randomized to the combination treatment and 2552 to the hormone therapy alone. Invasive disease-free survival was the primary endpoint of the study.

The median duration on study follow-up was 34 months, with three-year and two-year duration of ribociclib completed by 20% and 57% patients respectively. Invasive disease-free survival was evaluated after 426 events.

At the time of this analysis, 189 people in the ribociclib group (7.4% of patients) experienced an invasive disease-free survival event, compared to 237 people in the hormone therapy alone group (9.3% of patients). The data showed a statistically significant improvement in the risk of invasive disease in favor of the combination arm.  

The invasive disease-free survival rates at three years were 90.4%, compared to 87.1% for women who were treated with only hormone therapy.

Ribociclib at 400 mg had a favorable safety profile with no new signals.

“Overall, the combination therapy showed more favorable outcomes, significantly reducing the risk of the cancer returning,” Slamon said. “These results should change how we evaluate and treat patients.”

The study was sponsored by Novartis, which developed ribociclib at the Novartis Institutes for BioMedical Research under a research collaboration with Astex Pharmaceuticals.

END


ELSE PRESS RELEASES FROM THIS DATE:

New research suggests wheat crops may be threatened by unprecedented heat and drought

2023-06-02
The world is getting hotter, causing shifts in seasonal patterns and increasing the amount of extreme weather such as severe droughts and heat waves, which can affect crop yields and food supplies. A recent study led by a researcher at the Friedman School of Nutrition Science and Policy at Tufts University found that the likelihood of extreme temperatures that could affect crop yields has increased significantly in wheat-producing regions of the U.S. and China.  The findings predict heat waves that happened approximately ...

Eventually everything will evaporate, not only black holes

2023-06-02
New theoretical research by Michael Wondrak, Walter van Suijlekom and Heino Falcke of Radboud University has shown that Stephen Hawking was right about black holes, although not completely. Due to Hawking radiation, black holes will eventually evaporate, but the event horizon is not as crucial as had been believed. Gravity and the curvature of spacetime cause this radiation too. This means that all large objects in the universe, like the remnants of stars, will eventually evaporate. Using a clever combination of quantum physics and Einstein’s theory of gravity, Stephen Hawking argued that the spontaneous creation and annihilation ...

Underwater forest's recovery offers hope for marine restoration across the globe

2023-06-02
Human activity has degraded ecosystems and damaged biodiversity around the world, but ecosystem restoration offers hope for the future. Scientists studying the restoration of underwater seaweed forests which provide other species with food and shelter have found that 10 years of restoration efforts have helped a damaged forest regrow to richness and strength comparable to forests that have never been disturbed. “Macroalgal forests are found along over one-third of the world’s coastlines and underpin ...

Developing technologies to reduce the cost of green hydrogen production

Developing technologies to reduce the cost of green hydrogen production
2023-06-02
Green hydrogen, which produces hydrogen without the use of fossil fuels or the emission of carbon dioxide, has become increasingly important in recent years as part of efforts to realize a decarbonized economy. However, due to the high production cost of water electrolysis devices that produce green hydrogen, the economic feasibility of green hydrogen has not been very high. However, the development of a technology that drastically reduces the amount of rare metals such as iridium and platinum used in polymer electrolyte membrane water electrolysis devices is opening the way to lower production costs. A research team led by Dr. Hyun S. Park and Sung Jong ...

ASCO 2023 - Sylvester Comprehensive Cancer Center experts available for interviews

2023-06-02
Sarcomas Dr. Jonathan C. Trent, a medical oncologist specializing in Sarcoma and Connective Tissue Medical Oncology at Sylvester, is available to discuss a wide range of issues related to Sarcoma research and experimental therapeutics. He and collaborators are involved in multiple ASCO23 presentations, including: Multi-omic characterization of gastrointestinal stromal tumor (GIST) in a large real-world patient cohort. Outcomes in patients with advanced gastrointestinal stromal tumor who did not have ...

Alcohol dependency in adolescence, but not consumption, linked with later depression risk

2023-06-02
Adolescents who show signs of alcohol dependence are more likely to develop depression by their mid-20s, according to a new study led by UCL (University College London) and University of Bristol researchers. Drinking large amounts of alcohol regularly, but with no signs of dependency, did not predict depression risk, according to the findings published in The Lancet Psychiatry. Co-lead author Dr Gemma Lewis (UCL Psychiatry) said: “By using a large, longitudinal dataset, we have found evidence that problematic drinking patterns in late adolescence may increase the risk of developing ...

Why we need to fall out of love with flaky white fish - study

2023-06-02
The UK’s growing mismatch between the fish we catch and the fish we want to eat has clear implications for our future food security, according to new research.  Led by the University of Essex and the Centre for Environment Fisheries and Aquaculture Science (Cefas), the study, published in the international peer-reviewed journal Reviews in Fish Biology and Fisheries, for the first time offers a comprehensive, long-term analysis of how major policy changes in the past 120 years have influenced patterns in UK seafood production, trade and consumption.  It shows that even if we changed our fish-eating habits away from choosing flaky white fish such as cod ...

UK’s poorest children likelier to have less understanding of personal finances, study finds

2023-06-02
A new study of 3,745 families from across the UK demonstrates a “sizeable” gap in the financial knowledge of children depending on which socio-economic group they come from. The research highlights significant inequalities in young people’s financial capabilities, with the results pointing toward disadvantaged children not developing key financial skills. In findings published in the peer-reviewed British Journal of Educational Studies, an expert team from UCL are calling for a greater emphasis on developing financial skills amongst children starting at primary school, particularly aimed towards those from disadvantaged social backgrounds, with “a particular need ...

ASCO 23: Thyroid cancer precision approaches that incorporate targeted therapies and other treatments are changing the surgeon’s role

ASCO 23: Thyroid cancer precision approaches that incorporate targeted therapies and other treatments are changing the surgeon’s role
2023-06-02
DOWNLOADABLE B-ROLL/VIDEO   MIAMI, FLORIDA (June 1, 2023) – Historically, surgery was the first line of treatment for patients with thyroid cancer. Now, as targeted therapies and other new medications emerge, surgery for certain patients may become more of a secondary option if those treatments fail. This new context could potentially change how some procedures are conducted. Otolaryngologist and head and neck surgeon Dr. Zoukaa Sargi, will join a June 2 panel discussion on thyroid cancer care ...

Medical College of Wisconsin cancer researcher & key investigator on study of Pirtobrutinib, now FDA approved for patients previously treated for Mantle Cell Lymphoma

2023-06-02
In a multicenter phase 1 and 2 trial (BRUIN, NCT03740529), researchers from leading cancer centers across the globe, including the Medical College of Wisconsin (MCW) in Milwaukee, tested Bruton tyrosine kinase inhibitor (BTKi), pirtobrutinib, in patients with pre-treated mantle cell lymphoma (MCL). Results of the study, which assessed the efficacy of the drug in a cohort of 90 patients with poor survival prognosis, demonstrated the reversible BTKi drug to be both safe and effective in achieving inhibition of defective B-cells. The results were published by the Journal of Clinical Oncology on May 16.   MCL is an aggressive, rare subtype of ...

LAST 30 PRESS RELEASES:

“Quantum squeezing” a nanoscale particle for the first time

El Niño spurs extreme daily rain events despite drier monsoons in India

Two studies explore the genomic diversity of deadly mosquito vectors

Zebra finches categorize their vocal calls by meaning

Analysis challenges conventional wisdom about partisan support for US science funding

New model can accurately predict a forest’s future

‘Like talking on the telephone’: Quantum computing engineers get atoms chatting long distance

Genomic evolution of major malaria-transmitting mosquito species uncovered

Overcoming the barriers of hydrogen storage with a low-temperature hydrogen battery

Tuberculosis vulnerability of people with HIV: a viral protein implicated

Partnership with Kenya's Turkana community helps scientists discover genes involved in adaptation to desert living

Decoding the selfish gene, from evolutionary cheaters to disease control

Major review highlights latest evidence on real-time test for blood – clotting in childbirth emergencies

Inspired by bacteria’s defense strategies

Research spotlight: Combination therapy shows promise for overcoming treatment resistance in glioblastoma

University of Houston co-leads $25 million NIH-funded grant to study the delay of nearsightedness in children

NRG Oncology PREDICT-RT study completes patient accrual, tests individualized concurrent therapy and radiation for high-risk prostate cancer

Taking aim at nearsightedness in kids before it’s diagnosed

With no prior training, dogs can infer how similar types of toys work, even when they don’t look alike

Three deadliest risk factors of a common liver disease identified in new study

Dogs can extend word meanings to new objects based on function, not appearance

Palaeontology: South American amber deposit ‘abuzz’ with ancient insects

Oral microbes linked to increased risk of pancreatic cancer

Soccer heading does most damage to brain area critical for cognition

US faces rising death toll from wildfire smoke, study finds

Scenario projections of COVID-19 burden in the US, 2024-2025

Disparities by race and ethnicity in percutaneous coronary intervention

Glioblastoma cells “unstick” from their neighbors to become more deadly

Oral bacterial and fungal microbiome and subsequent risk for pancreatic cancer

New light on toxicity of Bluefin tuna

[Press-News.org] ASCO: Adding ribociclib to hormone therapy improves outcomes in patients with early breast cancer
The addition of ribociclib reduced the risk of the cancer returning by 25%